Modulating role of dopamine on anesthetic requirements

Ira S. Segal, John K. Walton, Ian Irwin, Louis E. DeLanney, George Ricaurte, J. William Langston, Mervyn Maze

Research output: Contribution to journalArticle

Abstract

The influence of dopamine on halothane anesthetic requirements was determined in mice. Halothane anesthetic requirement was defined as the minimum anesthetic concentration (MAC) that prevented 50% animals from moving in response to a supramaximal stimulus. Levodopa (L-DOPA) dose-dependently decreased halothane MAC to a maximum of 49% of control; over the same dose range L-DOPA increased striatal dopamine nearly 4-fold. The MAC-reducing effect of L-DOPA was attenuated by selective antagonism of the D2 dopamine receptor with YM-09151-2 while selective blockade of the D1 dopamine receptor with SCH-23390 did not alter L-DOPA's effect on the MAC for halothane. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) decreased striatal dopamine by 82% and increased the MAC for halothane by 27%. Repletion of striatal dopamine with L-DOPA, in MPTP-treated mice, restored the MAC for halothane back to the control state. The regression line derived from the plot of hatothane MAC versus striatal dopamine content shows a highly significant correlation between the two variables (r2 = 0.94). These are the first results to suggest that anesthetic requirements can be modulated directly and precisely by increasing or decreasing the content of a single neurotransmitter in the central nervous system.

Original languageEnglish (US)
Pages (from-to)9-15
Number of pages7
JournalEuropean Journal of Pharmacology
Volume186
Issue number1
DOIs
StatePublished - Sep 4 1990
Externally publishedYes

Fingerprint

Anesthetics
Dopamine
Halothane
Corpus Striatum
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Dopamine D1 Receptors
Dopamine D2 Receptors
Levodopa
Neurotransmitter Agents
Central Nervous System

Keywords

  • Anesthetics (volatile)
  • Dopamine D receptors
  • Dopamine receptors
  • Halothane
  • Parkinsons disease

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Segal, I. S., Walton, J. K., Irwin, I., DeLanney, L. E., Ricaurte, G., Langston, J. W., & Maze, M. (1990). Modulating role of dopamine on anesthetic requirements. European Journal of Pharmacology, 186(1), 9-15. https://doi.org/10.1016/0014-2999(90)94055-3

Modulating role of dopamine on anesthetic requirements. / Segal, Ira S.; Walton, John K.; Irwin, Ian; DeLanney, Louis E.; Ricaurte, George; Langston, J. William; Maze, Mervyn.

In: European Journal of Pharmacology, Vol. 186, No. 1, 04.09.1990, p. 9-15.

Research output: Contribution to journalArticle

Segal, IS, Walton, JK, Irwin, I, DeLanney, LE, Ricaurte, G, Langston, JW & Maze, M 1990, 'Modulating role of dopamine on anesthetic requirements', European Journal of Pharmacology, vol. 186, no. 1, pp. 9-15. https://doi.org/10.1016/0014-2999(90)94055-3
Segal, Ira S. ; Walton, John K. ; Irwin, Ian ; DeLanney, Louis E. ; Ricaurte, George ; Langston, J. William ; Maze, Mervyn. / Modulating role of dopamine on anesthetic requirements. In: European Journal of Pharmacology. 1990 ; Vol. 186, No. 1. pp. 9-15.
@article{3a5f11c1d1a444f988cfca2b53bf51f6,
title = "Modulating role of dopamine on anesthetic requirements",
abstract = "The influence of dopamine on halothane anesthetic requirements was determined in mice. Halothane anesthetic requirement was defined as the minimum anesthetic concentration (MAC) that prevented 50{\%} animals from moving in response to a supramaximal stimulus. Levodopa (L-DOPA) dose-dependently decreased halothane MAC to a maximum of 49{\%} of control; over the same dose range L-DOPA increased striatal dopamine nearly 4-fold. The MAC-reducing effect of L-DOPA was attenuated by selective antagonism of the D2 dopamine receptor with YM-09151-2 while selective blockade of the D1 dopamine receptor with SCH-23390 did not alter L-DOPA's effect on the MAC for halothane. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) decreased striatal dopamine by 82{\%} and increased the MAC for halothane by 27{\%}. Repletion of striatal dopamine with L-DOPA, in MPTP-treated mice, restored the MAC for halothane back to the control state. The regression line derived from the plot of hatothane MAC versus striatal dopamine content shows a highly significant correlation between the two variables (r2 = 0.94). These are the first results to suggest that anesthetic requirements can be modulated directly and precisely by increasing or decreasing the content of a single neurotransmitter in the central nervous system.",
keywords = "Anesthetics (volatile), Dopamine D receptors, Dopamine receptors, Halothane, Parkinsons disease",
author = "Segal, {Ira S.} and Walton, {John K.} and Ian Irwin and DeLanney, {Louis E.} and George Ricaurte and Langston, {J. William} and Mervyn Maze",
year = "1990",
month = "9",
day = "4",
doi = "10.1016/0014-2999(90)94055-3",
language = "English (US)",
volume = "186",
pages = "9--15",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Modulating role of dopamine on anesthetic requirements

AU - Segal, Ira S.

AU - Walton, John K.

AU - Irwin, Ian

AU - DeLanney, Louis E.

AU - Ricaurte, George

AU - Langston, J. William

AU - Maze, Mervyn

PY - 1990/9/4

Y1 - 1990/9/4

N2 - The influence of dopamine on halothane anesthetic requirements was determined in mice. Halothane anesthetic requirement was defined as the minimum anesthetic concentration (MAC) that prevented 50% animals from moving in response to a supramaximal stimulus. Levodopa (L-DOPA) dose-dependently decreased halothane MAC to a maximum of 49% of control; over the same dose range L-DOPA increased striatal dopamine nearly 4-fold. The MAC-reducing effect of L-DOPA was attenuated by selective antagonism of the D2 dopamine receptor with YM-09151-2 while selective blockade of the D1 dopamine receptor with SCH-23390 did not alter L-DOPA's effect on the MAC for halothane. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) decreased striatal dopamine by 82% and increased the MAC for halothane by 27%. Repletion of striatal dopamine with L-DOPA, in MPTP-treated mice, restored the MAC for halothane back to the control state. The regression line derived from the plot of hatothane MAC versus striatal dopamine content shows a highly significant correlation between the two variables (r2 = 0.94). These are the first results to suggest that anesthetic requirements can be modulated directly and precisely by increasing or decreasing the content of a single neurotransmitter in the central nervous system.

AB - The influence of dopamine on halothane anesthetic requirements was determined in mice. Halothane anesthetic requirement was defined as the minimum anesthetic concentration (MAC) that prevented 50% animals from moving in response to a supramaximal stimulus. Levodopa (L-DOPA) dose-dependently decreased halothane MAC to a maximum of 49% of control; over the same dose range L-DOPA increased striatal dopamine nearly 4-fold. The MAC-reducing effect of L-DOPA was attenuated by selective antagonism of the D2 dopamine receptor with YM-09151-2 while selective blockade of the D1 dopamine receptor with SCH-23390 did not alter L-DOPA's effect on the MAC for halothane. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) decreased striatal dopamine by 82% and increased the MAC for halothane by 27%. Repletion of striatal dopamine with L-DOPA, in MPTP-treated mice, restored the MAC for halothane back to the control state. The regression line derived from the plot of hatothane MAC versus striatal dopamine content shows a highly significant correlation between the two variables (r2 = 0.94). These are the first results to suggest that anesthetic requirements can be modulated directly and precisely by increasing or decreasing the content of a single neurotransmitter in the central nervous system.

KW - Anesthetics (volatile)

KW - Dopamine D receptors

KW - Dopamine receptors

KW - Halothane

KW - Parkinsons disease

UR - http://www.scopus.com/inward/record.url?scp=0025100585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025100585&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(90)94055-3

DO - 10.1016/0014-2999(90)94055-3

M3 - Article

VL - 186

SP - 9

EP - 15

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1

ER -